Today's decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB). Azithromyc...
Read the complete post at http://media.netpr.pl/notatka_103437.html